Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Acquisitions (2017 - 2021)

Aytu Biopharma (AYTU) has disclosed Acquisitions for 5 consecutive years, with -$202000.0 as the latest value for Q2 2021.

  • On a quarterly basis, Acquisitions fell 103.7% to -$202000.0 in Q2 2021 year-over-year; TTM through Jun 2021 was -$129607.0, a 279.03% decrease, with the full-year FY2021 number at $15.5 million, up 165.3% from a year prior.
  • Acquisitions was -$202000.0 for Q2 2021 at Aytu Biopharma, down from $15.4 million in the prior quarter.
  • In the past five years, Acquisitions ranged from a high of $15.4 million in Q1 2021 to a low of -$5.4 million in Q2 2017.
  • A 3-year average of $3.8 million and a median of $2.6 million in 2020 define the central range for Acquisitions.
  • Biggest YoY gain for Acquisitions was 103.7% in 2021; the steepest drop was 103.7% in 2021.
  • Aytu Biopharma's Acquisitions stood at -$5.4 million in 2017, then surged by 201.34% to $5.5 million in 2020, then crashed by 103.7% to -$202000.0 in 2021.
  • Per Business Quant, the three most recent readings for AYTU's Acquisitions are -$202000.0 (Q2 2021), $15.4 million (Q1 2021), and $5.5 million (Q2 2020).